CIAM
CLDX icon

Caitong International Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Caitong International Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$83.3K Buy
2,625
+2,603
+11,832% +$71K 0.02% 632
2025
Q4 		$598 Buy
+22
New +$579 ﹤0.01% 1445
2025
Q3 		– Sell
-78
Closed -$1.59K – 2025
2025
Q2 		$1.59K Buy
78
+46
+144% +$895 ﹤0.01% 1450
2025
Q1 		$581 Buy
+32
New +$715 ﹤0.01% 1729

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Caitong International Asset Management's CLDX Position: Q1 2026 in Review

Caitong International Asset Management increased its Celldex Therapeutics (CLDX) stake by 11,832% in Q1 2026, buying an estimated $71K and bringing the position to 2,625 shares worth $83.3K. The position accounts for 0.02% of the portfolio, ranked #632.

Caitong International Asset Management first reported a position in CLDX in Q1 2025 and has held it in 4 quarters since. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Caitong International Asset Management held 2,625 shares of Celldex Therapeutics worth $83.3K as of Q1 2026.
  • Caitong International Asset Management bought 2,603 Celldex Therapeutics shares in Q1 2026, an estimated $71K.
  • Celldex Therapeutics made up 0.02% of Caitong International Asset Management's portfolio in Q1 2026, its #632 holding.
  • Caitong International Asset Management first reported a position in Celldex Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.